Cargando...
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
CTLA-4 is an immune checkpoint expressed on active anticancer T cells. When it combines with its ligand B7 on dendritic cells, it inhibits the activity of the T cells. The Bromo- and Extra-Terminal (BET) protein family includes proteins that regulate the expression of key oncogenes and antiapoptotic...
Gardado en:
| Publicado en: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
National Academy of Sciences
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003484/ https://ncbi.nlm.nih.gov/pubmed/29735668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1721559115 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|